United Kingdom

People: Chiasma Inc (CHMA.OQ)

CHMA.OQ on NASDAQ Stock Exchange Global Select Market

5:05pm BST
Change (% chg)

$0.22 (+4.33%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Mamluk, Roni 

Dr. Roni Mamluk, Ph.D., serves as Director of the Company. Dr. Mamluk currently serves as chief executive officer of Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. She served as our Chief Development Officer from March 2015 to March 2017 and has served as a director of Chiasma (Israel) Ltd. since April 2017. Dr. Mamluk served as our Chief Executive Officer from April 2013 to March 2015 and held various roles in the Company from 2006 to April 2013, including Chief Operating Officer and Vice President, Research and Development. She also served as a member of our Board of Directors from April 2013 to March 2015. Prior to joining us, Dr. Mamluk established and led nonclinical research and development at Adnexus Therapeutics, Inc. Dr. Mamluk received her B.A. and Ph.D. from the Hebrew University. She completed her post-doctoral fellowship at Children’s Hospital/Harvard Medical School in the field of angiogenesis. We believe that Dr. Mamluk’s long history with us, including her leading role in developing, and being one of the primary inventors of, our proprietary Transient Permeability Enhancer, or TPE, technology platform, and in developing our oral octreotide capsule product candidate, make her an important member of our Board of Directors.

Basic Compensation

Total Annual Compensation, USD 76,106
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 389,799
Fiscal Year Total, USD 465,905

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --